Feasibility of a type 1 diabetes primary prevention trial using 2000 IU vitamin D3 in infants from the general population with increased HLA-associated risk.
Recent epidemiologic, immunologic, and NOD mouse studies suggest that intervention in the vitamin D system may be a successful method to prevent type 1 diabetes. Newborns at increased HLA-associated risk are randomized to receive either 400 or 2000 IU vitamin D3 by 1 month of age. We show that recruitment of babies from the general population for identification of HLA-associated risk status followed by enrollment to a randomized controlled prevention trial is feasible in Canada.
Wicklow
Brandy A
BA
Winnipeg DVD Study Group, and Department of Pediatrics and Child Health, University of Manitoba, 685 William Avenue, Winnipeg, MB, Canada R3E 0Z2.
Taback
Shayne P
SP
D002118:Calcium / Q000097:blood / Q000652:urine; D002170:Canada / Q000453:epidemiology; D002762:Cholecalciferol / Q000627:therapeutic use*; D003922:Diabetes Mellitus, Type 1 / Q000453:epidemiology / Q000517:prevention & control*; D004305:Dose-Response Relationship, Drug; D005240:Feasibility Studies; D005500:Follow-Up Studies; D006680:HLA Antigens / Q000235:genetics*; D006801:Humans; D007231:Infant, Newborn; D010865:Pilot Projects; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome
D006680:HLA Antigens; D002762:Cholecalciferol; D002118:Calcium